The role of stavudine in the management of adults with HIV infection

Antiviral Therapy

Volumn 2, Issue 4, 1997, Pages 207-218

  Moyle, Graeme J ^a   Gazzard, Brian G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; BIOAVAILABILITY; DRUG EFFICACY; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; STAVUDINE;

EID: 0031434645     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (2)

1. BHIVA Guidelines Coordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349:1086-1092.
2. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996; 52:168-85.